A 26-year-old pregnant woman was referred to our center for scleronodular Hodgkin's disease (SHD). Due to clinical aggravation, the medical staff decided to perform 18 F-FDG positron emission tomography/ computed tomography (FDG-PET/CT) at 26 weeks of amenorrhea, with the patient's agreement. In case of advanced stage disease, a medical interruption of pregnancy and aggressive chemotherapy would have been performed [1] . The risk of a mistaged lymphoma appeared greater than the fetal risk of an optimized low-dose PET/CT procedure at this conception age.
FDG activity was decreased to 3 MBq/kg and CT parameters locked at 80 kV and 80 mAs without intensity modulation (which could have induced a dose increase due to the larger abdominal attenuation compare to the rest of the body). The calculated fetal dosimetry result was 4.1 mSv from FDG PET and 3.2 mSv from CT [2, 3] . Total fetal irradiation was ten times less than the 100 mSv malformative risk limit described by the International Commission on Radiological Protection [4, 5] . Depending on the FDG PET/CT procedure and fetal age, the fetal estimated dose ranged between 1.01 and 21.9 mGy in the 12 other published cases of FDG PET/ CT carried out during pregnancy that we found in the literature (Table 1 ) [5] [6] [7] [8] [9] [10] [11] .
The FDG PET/CT demonstrated a stage IIIA lymphoma ( Figs. 1 and 2 ) and led to treating the patient with corticotherapy as long as the SHD was free of progression. Fetal ultrasonography follow-up remained normal, and a healthy child was born via caesarean section at 36 weeks of amenorrhea. The patient received chemotherapy the day after delivery.
In conclusion, use of FDG PET/CT is conceivable during pregnancy for malignant lymphoma staging on medical decision, with an optimized low-dose protocol and with patient agreement. 
